{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:14:22Z","timestamp":1788891262923,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p>Immunosuppression non-adherence is a major cause of graft failure after liver transplantation. The aim of this study was to evaluate practice surrounding conversion from immediate-release to prolonged-release Tacrolimus formulation and to assess patient adherence and quality of life (QoL). One hundred and seven adult liver transplant recipients, receiving immediate-release Tacrolimus for a minimum of 6\u00a0months, were converted to prolonged-release formulation, based on a dose ratio of one (1:1). The median follow-up was 120 [IQR, 120\u2013123] months. Tacrolimus dosage and blood level, liver and renal function, lipid and glucose profiles were recorded. In addition, questionnaires were submitted to evaluate adherence and QoL following conversion. No rejection was recorded. The median serum Tacrolimus blood level decreased over 1\u00a0month (5.80, [IQR, 2.0\u201310.8] vs. 3.8 [IQR, 1.4\u20138.7]; <jats:italic>p<\/jats:italic> &amp;lt; 0.0005). Significant improvement in renal function was noted (median GFR was 81.7 [IQR, 43.4\u2013128.6] vs. 73.9 [IQR, 27.1\u2013130.2]; <jats:italic>p<\/jats:italic> = 0.0002). At the end of the follow-up, conversion resulted in an overall decrease in non-adherence of 53.3% (<jats:italic>p<\/jats:italic> = 0.0001) and an improvement in QoL was reported by 76.2% of patients. Thus, 1:1 conversion from immediate to prolonged-release Tacrolimus is safe, feasible and efficient, avoiding under-therapeutic and toxic peak concentrations, improving renal function, adherence to immunosuppression and overall patient QoL.<\/jats:p>","DOI":"10.3389\/ti.2022.10384","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T04:11:36Z","timestamp":1671423096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Renal Function, Adherence and Quality of Life Improvement After Conversion From Immediate to Prolonged-Release Tacrolimus in Liver Transplantation: Prospective Ten-Year Follow-Up Study"],"prefix":"10.3389","volume":"35","author":[{"given":"Luca","family":"Toti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso Maria","family":"Manzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Lenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Toschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tisone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46101681","DOI":"10.1016\/j.bpg.2020.101681","article-title":"Immunosuppression in Liver Transplant","author":"Di Maira","year":"","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.3748\/wjg.v25.i35.5356","article-title":"De Novo malignancies after Liver Transplantation: The Effect of Immunosuppression-Personal Data and Review of Literature","volume":"25","author":"Manzia","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/ijc.31552","article-title":"Risk of Virus and Non-virus Related Malignancies Following Immunosuppression in a Cohort of Liver Transplant Recipients. Italy, 1985-2014","volume":"143","author":"Taborelli","year":"","journal-title":"Italyint J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/ijc.31782","article-title":"Survival after the Diagnosis of De Novo Malignancy in Liver Transplant Recipients","volume":"144","author":"Taborelli","year":"2019","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e12981","DOI":"10.1111\/ctr.1298110.1111\/ctr.12981","article-title":"Medication Adherence and Rejection Rates in Older vs Younger Adult Liver Transplant Recipients","volume":"31","author":"Leven","year":"2017","journal-title":"Clin Transpl"},{"key":"B6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/tri.12312","article-title":"Describing the Evolution of Medication Nonadherence from Pretransplant until 3 Years post-transplant and Determining Pretransplant Medication Nonadherence as Risk Factor for post-transplant Nonadherence to Immunosuppressives: the Swiss Transplant Cohort Study","volume":"27","author":"De Geest","year":"2014","journal-title":"Transpl Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jceh.2019.03.003","article-title":"Determinants of Medication Adherence in Liver Transplant Recipients","volume":"9","author":"Jain","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/lt.20828","article-title":"Adherence to Medication after Liver Transplantation in Scotland: a Pilot Study","volume":"12","author":"O'Carroll","year":"2006","journal-title":"Liver Transpl"},{"key":"B9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.amjsurg.2019.02.018","article-title":"Transplant Surgery Enters a new era: Increasing Immunosuppressive Medication Adherence through mobile Apps and Smart Watches","volume":"218","author":"Levine","year":"2019","journal-title":"Am J Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/01.tp.0000110408.83054.88","article-title":"Frequency and Impact of Nonadherence to Immunosuppressants after Renal Transplantation: a Systematic Review","volume":"77","author":"Butler","year":"2004","journal-title":"Transplantation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s10620-012-2412-0","article-title":"Non-adherence and Graft Failure in Adult Liver Transplant Recipients","volume":"58","author":"Lieber","year":"2013","journal-title":"Dig Dis Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/00007890-199211000-00010","article-title":"Late-onset Acute Rejection in Orthotopic Liver Transplantation-Aassociated Risk Factors and Outcome","volume":"54","author":"Mor","year":"1992","journal-title":"Transplantation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S1-S56","DOI":"10.1097\/TP.0000000000001651","article-title":"Practical Recommendations for Long-Term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group","volume":"101","author":"Neuberger","year":"2017","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.transproceed.2007.02.074","article-title":"Medication Adherence in Chronic Disease: Issues in Posttransplant Immunosuppression","volume":"39","author":"Hansen","year":"2007","journal-title":"Transpl Proc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.transproceed.2008.02.083","article-title":"Treatment Adherence in Renal Transplant Recipients: a Questionnaire Survey on Immunosuppressants","volume":"40","author":"Ichimaru","year":"2008","journal-title":"Transpl Proc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","article-title":"Tacrolimus: a Further Update of its Use in the Management of Organ Transplantation","volume":"63","author":"Scott","year":"2003","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.transproceed.2004.11.086","article-title":"Conversion of Stable Liver Transplant Recipients from a Twice-Daily Prograf-Based Regimen to a Once-Daily Modified Release Tacrolimus-Based Regimen","volume":"37","author":"Florman","year":"2005","journal-title":"Transpl Proc"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1097\/01.tp.0000265445.09987.f1","article-title":"Once-daily Tacrolimus Extended Release Formulation: Experience at 2 Years Postconversion from a Prograf-Based Regimen in Stable Liver Transplant Recipients","volume":"83","author":"Florman","year":"2007","journal-title":"Transplantation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/lt.23844","article-title":"Conversion from Twice Daily Tacrolimus Capsules to once Daily Extended-Release Tacrolimus (LCP-Tacro): Phase 2 Trial of Stable Liver Transplant Recipients","volume":"20","author":"Alloway","year":"2014","journal-title":"Liver Transpl"},{"key":"B21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1432-2277.2011.01412.x","article-title":"Renal Function, Efficacy and Safety Postconversion from Twice- to Once-Daily Tacrolimus in Stable Liver Recipients: an Open-Label Multicenter Study","volume":"25","author":"Sa\u0144ko-Resmer","year":"2012","journal-title":"Transpl Int"},{"key":"B22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/9781119634010.ch42","article-title":"Withdrawal of Immunosuppression after Liver Transplantation","volume-title":"Liver Transplantation: Clinical Assessment and Management","author":"Toti","year":"2021"},{"key":"B23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0004563220948886","article-title":"Assessment of Tacrolimus and Creatinine Concentration Collected Using Mitra Microsampling Devices","volume":"57","author":"Marshall","year":"2020","journal-title":"Ann Clin Biochem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2005.11.047","article-title":"Complete Weaning off Immunosuppression in HCV Liver Transplant Recipients Is Feasible and Favourably Impacts on the Progression of Disease Recurrence","volume":"44","author":"Tisone","year":"2006","journal-title":"J Hepatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1432-2277.2011.01254.x","article-title":"Efficacy, Safety, and Immunosuppressant Adherence in Stable Liver Transplant Patients Converted from a Twice-Daily Tacrolimus-Based Regimen to Once-Daily Tacrolimus Extended-Release Formulation","volume":"24","author":"Beckebaum","year":"2011","journal-title":"Transpl Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.transproceed.2011.01.130","article-title":"Switch from Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Kidney Transplantation","volume":"43","author":"Iaria","year":"2011","journal-title":"Transpl Proc"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.healun.2011.02.008","article-title":"Pharmacokinetics in Stable Heart Transplant Recipients after Conversion from Twice-Daily to Once-Daily Tacrolimus Formulations","volume":"30","author":"Alloway","year":"2011","journal-title":"J Heart Lung Transpl"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1111\/j.1600-6143.2010.03255.x","article-title":"Once-daily Prolonged-Release Tacrolimus (ADVAGRAF) versus Twice-Daily Tacrolimus (PROGRAF) in Liver Transplantation","volume":"10","author":"Trune\u010dka","year":"2010","journal-title":"Am J Transpl"},{"key":"B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and Functional Changes with the Aging Kidney","volume":"23","author":"Denic","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin Inhibitor Nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/sj.ki.5000270","article-title":"Progression of Kidney Dysfunction in the Community-Dwelling Elderly","volume":"69","author":"Hemmelgarn","year":"2006","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1291\/hypres.31.433","article-title":"Slower Decline of Glomerular Filtration Rate in the Japanese General Population: a Longitudinal 10-year Follow-Up Study","volume":"31","author":"Imai","year":"2008","journal-title":"Hypertens Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e12872","DOI":"10.1111\/ctr.12872","article-title":"Everolimus with Early Withdrawal or Reduced-Dose Calcineurin Inhibitors Improves Renal Function in Liver Transplant Recipients: A Systematic Review and Meta-Analysis","volume":"31","author":"Lin","year":"2017","journal-title":"Clin Transpl"},{"key":"B34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1054773810362039","article-title":"Medication Adherence in Older Renal Transplant Recipients","volume":"19","author":"Russell","year":"2010","journal-title":"Clin Nurs Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2147\/DDDT.S52820","article-title":"Increased Adherence Eight Months after Switch from Twice Daily Calcineurin Inhibitor Based Treatment to once Daily Modified Released Tacrolimus in Heart Transplantation","volume":"7","author":"Doesch","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.12659\/AOT.890101","article-title":"An Observational Study Evaluating Tacrolimus Dose, Exposure, and Medication Adherence after Conversion from Twice- to Once-Daily Tacrolimus in Liver and Kidney Transplant Recipients","volume":"19","author":"B\u00e4ckman","year":"2014","journal-title":"Ann Transpl"},{"key":"B37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/TP.0b013e3182725532","article-title":"Improved Adherence to Tacrolimus Once-Daily Formulation in Renal Recipients: a Randomized Controlled Trial Using Electronic Monitoring","volume":"95","author":"Kuypers","year":"2013","journal-title":"Transplantation"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2022.10384\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T04:11:39Z","timestamp":1671423099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2022.10384\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":37,"alternative-id":["10.3389\/ti.2022.10384"],"URL":"https:\/\/doi.org\/10.3389\/ti.2022.10384","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"article-number":"10384"}}